-
Product Insights
E Nash PV3 Solar PV Park
E Nash PV3 Solar PV Park is a solar PV project located in North Carolina, United States. The project is owned and being developed by Ecoplexus Inc. The project is expected to come online in 2025. Empower your strategies with our E Nash PV3 Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Efruxifermin in Liver Cirrhosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Efruxifermin in Liver Cirrhosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Efruxifermin in Liver Cirrhosis Drug Details: Efruxifermin (AKR-001) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Efruxifermin in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Efruxifermin in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Efruxifermin in Metabolic Dysfunction-Associated Steatotic Liver Disease...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Efruxifermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Efruxifermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Efruxifermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: Efruxifermin...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Insulin Human in Type 1 Diabetes (Juvenile Diabetes)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Insulin Human in Type 1 Diabetes (Juvenile Diabetes) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Insulin Human in Type 1 Diabetes (Juvenile Diabetes)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Miricorilant in Non-Alcoholic Steatohepatitis (NASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Miricorilant in Non-Alcoholic Steatohepatitis (NASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Miricorilant in Non-Alcoholic Steatohepatitis (NASH) Drug Details: Miricorilant (CORT-118335) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Resmetirom in Non-Alcoholic Steatohepatitis (NASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Resmetirom in Non-Alcoholic Steatohepatitis (NASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Resmetirom in Non-Alcoholic Steatohepatitis (NASH) Drug Details: Resmetirom (MGL-3196, VIA-3196) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Leronlimab in Non-Alcoholic Steatohepatitis (NASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Leronlimab in Non-Alcoholic Steatohepatitis (NASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Leronlimab in Non-Alcoholic Steatohepatitis (NASH) Drug Details: Leronlimab (PRO-140) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vutiglabridin in Non-Alcoholic Steatohepatitis (NASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vutiglabridin in Non-Alcoholic Steatohepatitis (NASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vutiglabridin in Non-Alcoholic Steatohepatitis (NASH) Drug Details: HSG-4112 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Efruxifermin in Non-Alcoholic Steatohepatitis (NASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Efruxifermin in Non-Alcoholic Steatohepatitis (NASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Efruxifermin in Non-Alcoholic Steatohepatitis (NASH) Drug Details: Efruxifermin (AKR-001) is under...